This is a ready-to-use self-inspection checklist for a GMP-regulated manufacturing site. It is organized around the same six systems FDA’s own inspection approach uses, so the exercise trains your team to think the way an inspector thinks rather than the way a document author thinks. Score each item Pass, Fail, or N/A with evidence, and route every Fail to CAPA. Replace every <<FILL: ...>> placeholder. A filled specimen follows.
Checklist control
| Field | Entry |
|---|---|
| Checklist number | <<FILL: CHK-ID>> |
| Site / operation | <<FILL>> |
| Self-inspection date(s) | <<FILL>> |
| Self-inspection team (names, functions, independence confirmed) | <<FILL>> |
| Scope | <<FILL: full site / single system / follow-up on prior findings>> |
| Parent SOP | <<FILL: SOP-ID for the self-inspection program>> |
1. Quality system
| # | Item | Ref | Result (P/F/NA) | Evidence / finding |
|---|---|---|---|---|
| 1.1 | Quality policy or quality manual is current, approved, and reflects how the site actually operates | 21 CFR 211.22 / ICH Q10 | <<FILL>> | <<FILL>> |
| 1.2 | All core QMS elements (document control, change control, deviations, CAPA, OOS, training, internal audit, management review) have current, followed procedures | ICH Q10 | <<FILL>> | <<FILL>> |
| 1.3 | Management review occurs at the defined frequency with real quality metrics that drive action, not a status slide | ICH Q10 | <<FILL>> | <<FILL>> |
| 1.4 | The quality unit can demonstrate it has actually rejected material, a procedure, or a batch, with no instance of an override by another function | 21 CFR 211.22 | <<FILL>> | <<FILL>> |
| 1.5 | The self-inspection program itself runs to its own schedule, and prior findings are tracked to closure with verified effectiveness | EU GMP Part I, Chapter 9 | <<FILL>> | <<FILL>> |
2. Facilities and equipment
| # | Item | Ref | Result (P/F/NA) | Evidence / finding |
|---|---|---|---|---|
| 2.1 | Facility design and material/personnel flow prevent mix-ups and cross-contamination | 21 CFR 211 Subpart C | <<FILL>> | <<FILL>> |
| 2.2 | HVAC, room classification, and pressure differentials are qualified and routinely monitored, with excursions investigated | 21 CFR 211 Subpart C | <<FILL>> | <<FILL>> |
| 2.3 | Equipment is qualified (IQ/OQ/PQ as applicable) for its intended use before production use | 21 CFR 211 Subpart D | <<FILL>> | <<FILL>> |
| 2.4 | Calibration is current for all instruments in GMP use, with no equipment run past its due date | Calibration program | <<FILL>> | <<FILL>> |
| 2.5 | Preventive maintenance is current, not backlogged, and cleaning validation or verification is current for shared equipment | 21 CFR 211.67 | <<FILL>> | <<FILL>> |
3. Materials
| # | Item | Ref | Result (P/F/NA) | Evidence / finding |
|---|---|---|---|---|
| 3.1 | Incoming materials are quarantined on receipt and cannot be dispensed until Quality changes their status to approved | 21 CFR 211 Subpart E | <<FILL>> | <<FILL>> |
| 3.2 | A certificate of analysis is on file and verified against the site’s own specification for each lot before release | 21 CFR 211 Subpart E | <<FILL>> | <<FILL>> |
| 3.3 | Supplier qualification is current for critical materials and active ingredients, with periodic requalification performed | Supplier qualification program | <<FILL>> | <<FILL>> |
| 3.4 | Rejected or quarantined materials are physically segregated and clearly labeled, not just flagged in a system | 21 CFR 211 Subpart E | <<FILL>> | <<FILL>> |
| 3.5 | Material status changes are enforced by the inventory or warehouse management system, not by procedure alone | 21 CFR 211 Subpart E | <<FILL>> | <<FILL>> |
4. Production
| # | Item | Ref | Result (P/F/NA) | Evidence / finding |
|---|---|---|---|---|
| 4.1 | Master batch records are approved, current, and match the validated process | 21 CFR 211.186 | <<FILL>> | <<FILL>> |
| 4.2 | Executed batch records are complete, contemporaneous, and show second-person verification on critical steps (line clearance, weighing) | 21 CFR 211.188 | <<FILL>> | <<FILL>> |
| 4.3 | Deviations are opened at the time an event is observed, not reconstructed afterward | Deviation management program | <<FILL>> | <<FILL>> |
| 4.4 | Environmental and in-process monitoring data (where applicable) is trended and reviewed, not only checked against a single limit | 21 CFR 211.113 | <<FILL>> | <<FILL>> |
| 4.5 | Line clearance is documented and verified before each batch or campaign starts | 21 CFR 211.67 | <<FILL>> | <<FILL>> |
5. Packaging and labeling
| # | Item | Ref | Result (P/F/NA) | Evidence / finding |
|---|---|---|---|---|
| 5.1 | Label reconciliation (issued, used, destroyed, returned) is performed and documented for every packaging run | 21 CFR 211.125 | <<FILL>> | <<FILL>> |
| 5.2 | Printed label storage and issuance controls prevent mix-up between similar labels or strengths | 21 CFR 211.122 | <<FILL>> | <<FILL>> |
| 5.3 | Packaging line clearance is documented before each run, including verification that the prior product and labeling are cleared | 21 CFR 211.130 | <<FILL>> | <<FILL>> |
| 5.4 | Artwork and label version control is tied to change control, so an outdated label version cannot be issued | Change control program | <<FILL>> | <<FILL>> |
6. Laboratory controls
| # | Item | Ref | Result (P/F/NA) | Evidence / finding |
|---|---|---|---|---|
| 6.1 | Analytical methods are validated or verified as applicable before routine use | 21 CFR 211.194 | <<FILL>> | <<FILL>> |
| 6.2 | Audit trail review is performed and documented at a defined frequency for computerized laboratory systems | 21 CFR Part 11 / Annex 11 | <<FILL>> | <<FILL>> |
| 6.3 | Out-of-specification investigations follow a two-phase structure (laboratory phase, then manufacturing phase if needed) and are closed within a defined timeframe | FDA OOS guidance | <<FILL>> | <<FILL>> |
| 6.4 | Reference standards are controlled, with traceable source, qualification, and expiry or requalification tracked | 21 CFR 211.194 | <<FILL>> | <<FILL>> |
| 6.5 | Second-person review of critical laboratory data (results, integrations, calculations) is documented, not assumed | 21 CFR 211.194 | <<FILL>> | <<FILL>> |
Scoring and sign-off
| Field | Entry |
|---|---|
| Total items / Pass / Fail / NA | <<FILL>> |
| Fails routed to CAPA (numbers) | <<FILL>> |
| Overall verdict | <<FILL: acceptable / conditional / not acceptable>> |
| Follow-up self-inspection date, if conditional | <<FILL>> |
| Role | Name | Signature | Date |
|---|---|---|---|
| Lead inspector | <<FILL>> | ||
| Site Quality Head | <<FILL>> |
References
21 CFR Part 211 (drug CGMP), Subparts C through J. ICH Q9, Quality Risk Management, and ICH Q10, Pharmaceutical Quality System. EU GMP Part I, Chapter 9 (Self-Inspection). FDA’s Quality System inspection approach (organizing an inspection around the quality, facilities and equipment, materials, production, packaging and labeling, and laboratory control systems). 21 CFR Part 11 and EU GMP Annex 11 (electronic records and audit trails), where computerized systems are in scope.
Confirm the current version and clause numbers of each reference before issue, and add the equivalent references for any additional jurisdiction the site operates under.
Filled specimen
The following shows a short extract from an example self-inspection at a sterile fill-finish site, so you can see the level of detail an inspector expects. The site, numbers, and findings are illustrative; replace them with your own.
| # | Item | Result | Evidence / finding |
|---|---|---|---|
| 1.4 | Quality unit reject authority never overridden | Pass | Reviewed 12 months of reject decisions; no instance of Production or site leadership reversing a QA reject |
| 2.4 | Calibration current | Fail | Two balances in the dispensing suite were 11 days overdue for calibration; both had been used to weigh three batches in that window. CAPA-2026-118 opened, batches placed on hold pending impact assessment |
| 4.3 | Deviations opened contemporaneously | Fail | Sampled 10 batch records; one deviation (a filter integrity test retest) was written up four days after the event, reconstructed from memory. CAPA-2026-119 opened |
| 6.2 | Audit trail review performed | Pass | HPLC-04 and HPLC-05 audit trail reviews current through the prior week, both signed by an independent reviewer |
The two Fails are exactly the pattern a self-inspection is supposed to catch before an external inspector does: equipment run past its calibration due date, and a deviation reconstructed after the fact rather than raised in real time. Both were routed to CAPA the same day, with the calibration Fail also triggering an immediate batch-impact assessment because product had already been made on the affected equipment.
Common inspection findings this checklist prevents
- Calibration or preventive maintenance backlogs that go unnoticed until an external inspector pulls the master equipment list.
- Deviations written up well after the event, with no contemporaneous evidence of when the problem was actually found.
- A self-inspection program that exists on paper but has not generated a finding in years, which invites the question of what is being missed.
- Material status changes that rely on a label or a procedure rather than a system control, creating a path for quarantined material to reach production.
- Audit trail reviews that are scheduled but not actually performed, discovered only when someone finally reads the log.
How to adapt this checklist
- Set the site, scope, and parent SOP in the control block.
- Add or remove items under each of the six systems to match your actual site footprint (for example, add sterile-specific items such as media fill status under Production if you run aseptic processing).
- Route every Fail to a CAPA number in the scoring block, and set a follow-up date if the overall verdict is conditional.
- Rotate the self-inspection team membership across cycles so the same people are not always checking their own area.
- Confirm every regulation and chapter reference in the References section against the current published version before issue. This checklist is educational guidance to adapt to your own site and quality system; it is not legal or regulatory advice, and completing it does not by itself demonstrate compliance with any cited regulation.